Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The systemic exposure to inhaled beclometasone/formoterol pMDI with valved holding chamber is independent of age and body size

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Assessing laryngeal function and hypersensitivity

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Optimal timing of influenza vaccine during pregnancy: A systematic review and meta-analysis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Fish-oil supplementation in pregnancy, child metabolomics and asthma risk

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. A Protocol for Extraction of Infective Viromes Suitable for Metagenomics Sequencing from Low Volume Fecal Samples

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Sensitivity of Multiple Breath Washout to Detect Mild to Moderate Asthma in Adolescence

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Maternal and fetal genetic effects on birth weight and their relevance to cardio-metabolic risk factors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Mirco Govoni
  • Annalisa Piccinno
  • Germano Lucci
  • Gianluigi Poli
  • Daniela Acerbi
  • Roberta Baronio
  • Dave Singh
  • Piotr Kuna
  • Bo L K Chawes
  • Hans Bisgaard
Vis graf over relationer

BACKGROUND: Asthma guidelines recommend prescription of inhaled corticosteroids at a reduced dosage in children compared to older patients in order to minimize the systemic exposure and risk of unwanted side effects. In children, pressurized metered dose inhalers (pMDI) are recommended in combination with a valved holding chamber (VHC) to overcome the problem of coordinating inhalation with actuation. However, the influence of age and body size on the systemic exposure of drugs to be administered via a pMDI with VHC is still not fully elucidated. Therefore, we aimed to compare the systemic exposure to the active ingredients of a fixed combination of beclometasone-dipropionate/formoterol-fumarate administered via pMDI with VHC in children, adolescents and adults.

METHODS: The pharmacokinetics of formoterol and beclometasone-17-monopropionate (active metabolite of beclometasone-dipropionate) was evaluated over 8 h from three studies, each performed in a different age and body size group. Children (7-11 years, n = 20), adolescents (12-17 years, n = 29) and adults (≥18 years, n = 24) received a single dose of beclometasone/formoterol (children: 200 μg/24 μg, adolescents and adults: 400 μg/24 μg) via pMDI with AeroChamber Plus™.

RESULTS: The systemic exposure in children in comparison to adolescents was equivalent for formoterol while it was halved for beclometasone-17-monopropionate in accordance with the halved dose of beclometasone administered in children (90% CIs within 0.8-1.25 for formoterol and 0.4-0.625 for beclometasone-17-monopropionate). The systemic exposure to beclometasone-17-monopropionate and formoterol was equivalent between adolescents and adults.

CONCLUSIONS: The systemic exposure to the active ingredients of a fixed dose combination of beclometasone/formoterol administered via pMDI with AeroChamber Plus™ correlates with the nominal dose independently of patient age and body size. Thus, dose reduction in relation to age when using a pMDI with VHC may be unnecessary for reducing the systemic exposure in children.

OriginalsprogEngelsk
TidsskriftPulmonary Pharmacology and Therapeutics
Vol/bind30
Sider (fra-til)102-109
Antal sider8
ISSN1094-5539
DOI
StatusUdgivet - 16 apr. 2014

ID: 45051061